Financial Statements · From SEC 10-K & 10-Q XBRL Filings
Crinetics Pharmaceuticals Inc. Revenue & Financial Statements
Crinetics Pharmaceuticals Inc. reported revenue of $7.7M for the fiscal year ended December 31, 2025, up 640.7% year over year, with net income of $(465.3M) and diluted EPS of $-4.95.
- Company
- Crinetics Pharmaceuticals Inc. CRNX · NASDAQ
- Latest fiscal year
- FY ended Dec 31, 2025
- Statements
- Income · Balance Sheet · Cash Flow — 5 fiscal years, 8 quarters
Income Statement
Annual, as reported in 10-K filings. Values in USD.
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 4.0M | 1.0M | 7.7M |
| Cost of revenue | — | — | — | — | 1.1M |
| Gross profit | — | — | — | — | 6.6M |
| Operating income | (107.7M) | (167.9M) | (222.6M) | (338.9M) | (516.8M) |
| Pretax income | 82K | (743K) | (502K) | (497K) | (11.5M) |
| Net income | (108.0M) | (167.5M) | (209.6M) | (298.4M) | (465.3M) |
| Diluted EPS | — | -3.15 | -3.69 | -3.69 | -4.95 |
| EBITDA | (106.8M) | (166.9M) | (221.5M) | (336.1M) | (512.9M) |
Quarterly
| USD | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 640K | 399K | 0 | — | 361K | 1.0M | 143K | 6.2M |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | (73.5M) | (82.8M) | (87.8M) | (94.7M) | (111.4M) | (129.1M) | (142.6M) | (133.7M) |
| Pretax income | — | — | — | — | — | — | — | — |
| Net income | (67.8M) | (74.4M) | (74.6M) | (81.7M) | (95.7M) | (116.0M) | (129.5M) | (122.8M) |
| Diluted EPS | -0.93 | -0.94 | -0.96 | -0.87 | -1.04 | -1.23 | -1.38 | -1.29 |
| EBITDA | (73.1M) | — | (87.0M) | (94.0M) | (110.5M) | — | (141.6M) | (132.7M) |
Balance Sheet
Fiscal year-end snapshots. Values in USD.
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Total assets | 351.0M | 352.2M | 635.4M | 1.4B | 1.1B |
| Current assets | 344.7M | 345.2M | 574.2M | 1.4B | 1.0B |
| Cash & equivalents | 200.7M | 32.7M | 54.9M | 264.5M | 101.5M |
| Total liabilities | 19.1M | 35.8M | 96.2M | 109.8M | 134.2M |
| Current liabilities | 16.0M | 27.7M | 43.9M | 59.7M | 85.1M |
| Long-term debt | — | — | — | — | — |
| Total debt | — | — | — | — | — |
| Stockholders’ equity | 331.9M | 316.3M | 539.1M | 1.3B | 992.1M |
| Net debt | — | — | — | — | — |
Cash Flow Statement
Annual, as reported in 10-K filings. Values in USD.
| USD | FY2022 | FY2023 | FY2024 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Operating cash flow | (115.2M) | (166.3M) | — | (226.0M) | (377.9M) |
| Investing cash flow | (174.0M) | (200.4M) | — | (574.8M) | 173.9M |
| Financing cash flow | 122.0M | 388.9M | — | 1.0B | 40.6M |
| Capital expenditure | 1.7M | 4.7M | — | 3.8M | 5.8M |
| Free cash flow | (116.9M) | (171.0M) | — | (229.8M) | (383.7M) |
| Dividends paid | — | — | — | — | — |
| Stock-based compensation | 28.3M | 40.9M | — | 69.4M | 91.0M |
Figures are parsed from SEC XBRL company facts and may be derived where issuers report year-to-date values (quarterly figures differenced; Q4 computed as FY minus Q3). Fiscal periods follow each company's fiscal calendar, not calendar years. Historical fact, not investment advice — verify with official SEC filings.
Every CRNX filing, connected
Financials beside price, insider trades, and 8-K events — with alerts the moment something new is filed.